COMP <GO>
JAZZ vs ELAN // NET PROFIT MARGIN
Jazz Pharmaceuticals plc (Ireland) (NASDAQ) VS. Elanco Animal Health Incorporated (NYSE) • 15-METRIC TALLY: JAZZ 4
— ELAN 6
▲ NET PROFIT MARGIN LEADER: ELAN
LAST: $229.74 (+7.14%) • MKT CAP: $13.92B
net-margins
-8.30%
LAST: $24.57 (+1.95%) • MKT CAP: $12.04B
net-margins
-4.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (JAZZ VS. ELAN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | JAZZ | ELAN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 55.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -4.70% | -2.50% | -2.20 | ELAN | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 9.61% | 2.45% | +7.16 | JAZZ | /fcf-yield <GO> |
| Operating Margin | -10.10% | -6.00% | -4.10 | ELAN | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -8.30% | -4.90% | -3.40 | ELAN | /net-margins <GO> |
| Revenue Growth (YoY) | 4.90% | 6.20% | -1.30 | ELAN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.97 | 1.24 | +0.73 | JAZZ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.0 | 63.3 | -16.30 | ELAN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 0.96 | +0.13 | JAZZ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.0x | 20.0x | +16.00 | ELAN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $13.92B | $12.04B | $1.88B | JAZZ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | JAZZ REV | ELAN REV | JAZZ GROSS % | ELAN GROSS % | JAZZ FCF | ELAN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.27B | $4.71B | — | 55.0% | $1.30B | $284.0M |
| FY 2024 | $4.07B | $4.44B | — | 54.9% | $1.36B | $394.0M |
| FY 2023 | $3.83B | $4.42B | — | — | $919.5M | $72.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
JAZZ // BETA 1.09
ELAN // BETA 0.96